Elcelyx's NewMet could fill diabetes niche
This article was originally published in Scrip
If Elcelyx Therapeutics's hypothesis about how metformin works in type 2 diabetes patients is confirmed in an ongoing Phase IIb clinical trial for the San Diego company's delayed-release metformin product called NewMet, the drug could become a viable therapy for millions of patients who are unable to take the widely prescribed generic medicine.
You may also be interested in...
Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.
The company and partner Vifor said the selective complement 5a receptor inhibitor met both primary and multiple secondary endpoints; US and EU filings are planned for 2020.